Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. (Q50925372)
Jump to navigation
Jump to search
scientific article published on 5 June 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. |
scientific article published on 5 June 2013 |
Statements
1 reference
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. (English)
1 reference
Panna Sanga
1 reference
Nathaniel Katz
1 reference
Elena Polverejan
1 reference
Steven Wang
1 reference
Kathleen M Kelly
1 reference
Juergen Haeussler
1 reference
John Thipphawong
1 reference
5 June 2013
1 reference
1 reference
154
1 reference
10
1 reference
1910-1919
1 reference
Identifiers
1 reference